Renata Block, MMS, PA-C

Renata Block spoke at the 2025 SDPA Fall Conference about her session on the use of artificial intelligence tools in clinical practice.

An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.

An expert in dermatology highlights emerging biologic therapy for the management of HS.

Renata Block, MMS, PA-C, comments on the use of biologic agents as part of immunomodulatory therapy for HS treatment.

An expert in dermatology reviews the current standard of care for treating patients with mild-to-moderate HS and discusses unmet needs in the clinical management of the condition.

Renata Block, MMS, PA-C, provides insight on the prevalence, symptoms, and predisposing factors that contribute to hidradenitis suppurativa (HS).